PD18 cytomegalovirus prophylaxis with valganciclovir for HIV-immunosuppressed patients: cost effectiveness and budget impact analysis from the Brazilian healthcare system perspective

Página do item simplificado
dc.creatorLudmila Peres Gargano
dc.creatorAriane André
dc.creatorIsabela Freitas
dc.creatorFrancisco de Assis Acurcio
dc.creatorJuliana Alvares Teodoro
dc.creatorAugusto Afonso Guerra Júnior
dc.date.accessioned2026-01-16T19:24:02Z
dc.date.issued2025-01-07
dc.descriptionPôster apresentado no HTAi 2024, encontro que ocorreu em Sevilha, na Espanha.
dc.identifier.doihttps://doi.org/10.1017/S0266462324002848
dc.identifier.issn1471-6348
dc.identifier.urihttps://hdl.handle.net/1843/1437
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofInternational Journal of Technology Assessment in Health Care
dc.rightsAcesso aberto
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Brazilen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/br/
dc.subjectAssistência farmacêutica
dc.subject.otherPacientes
dc.subject.otherHIV
dc.subject.otherSistema Único de Saúde
dc.titlePD18 cytomegalovirus prophylaxis with valganciclovir for HIV-immunosuppressed patients: cost effectiveness and budget impact analysis from the Brazilian healthcare system perspective
dc.typeArtigo de periódico
local.citation.volume40
local.description.resumoIntroduction Cytomegalovirus (CMV) infections are usually mild but can lead to serious consequences in immunocompromised patients, such as those infected with human immunodeficiency virus (HIV). Valganciclovir, which is approved for treating CMV, may be a cost-effective prophylactic for CMV disease in immunocompromised patients. Cost-effectiveness and budget impact analyses were conducted to compare valganciclovir prophylaxis with no prophylaxis in immunosuppressed patients with HIV. Methods Immunosuppressed patients with HIV who were seropositive for CMV were modeled in a one-year horizon decision tree. Outcomes were occurrence of CMV end-organ disease (EOD)–retinitis and gastroenteritis (85 and 15 percent of cases, respectively)–and survival probability after EOD. Direct medical costs related to prophylaxis (induction and maintenance phases) and treatment of EOD were considered. The budget impact analysis (BIA) used the clinical and cost parameters of the cost-effectiveness analysis to compare scenarios with valganciclovir prophylaxis and no prophylaxis in the public health system over a five-year time horizon. The annual market share adoption rate used was 10 percent. The number of eligible patients was calculated from HIV and acquired immunodeficiency syndrome cases reported in the country and epidemiological estimates. Results Valganciclovir prophylaxis had an incremental cost of BRL31,781 (USD6,531) and added 0.69 percent in one-year survival, resulting in an incremental cost-effectiveness ratio (ICER) of BRL4,610,022 (USD947,414) per death avoided in one year. The annual budget impact ranged from BRL35,660,931 (USD7,328,743) in the first year to BRL457,707,796 (USD94,064,365) in the fifth year, totaling BRL1,230,400,576 (USD252,861,870) over five years. In sensitivity analyses, the lack of a maximum treatment time for the maintenance phase with valganciclovir (50 to 365 days per year) resulted in a wide variation in the ICER and BIA results. Conclusions Despite being recommended for the treatment of CMV retinitis, the use of valganciclovir in immunocompromised patients with HIV who are seropositive for CMV but have not developed CMV disease has a higher ICER when compared with no prophylaxis. For these patients, appropriate use of standard antiretroviral therapy to improve the immune system may be more appropriate.
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIAL
local.publisher.initialsUFMG
local.subject.cnpqCIENCIAS DA SAUDE
local.url.externahttps://resolve.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/pd18-cytomegalovirus-prophylaxis-with-valganciclovir-for-hivimmunosuppressed-patients-cost-effectiveness-and-budget-impact-analysis-from-the-brazilian-healthcare-system-perspective/70B2ACAEF66B78D00E1776247B3CD117

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Pd18 cytomegalovirus prophylaxis with valganciclovir for hiv-immunosuppressed patients cost effectiveness and budget impact analysis from the brazilian healthcare system perspective.pdf
Tamanho:
38.21 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
license.txt
Tamanho:
2.07 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG